Based on your experience, what's your view on that perception
Revision may be considered for weight regain, inadequate weight loss, reflux, swallowing problems, band complications, or other concerns after a previous bariatric procedure
The 3 to 8 percentage point advantage over competitors in clinical data is a direct reflection of this additional mechanism of action
Retatrutide is an investigational triple agonist acting on GLP-1, GIP, and glucagon receptors, but it has not received MHRA marketing authorisation and cannot be legally prescribed in the UK
Several studies have estimated the costeffectiveness of GLP1s for obesity from a healthcare perspective, considering costs for screening and treatment against savings from improved weight and health outcomes and corresponding longterm reductions in healthcare utilization, including downstream accumulated health benefits
This can include speaking with a doctor or meeting certain BMI requirements